Granulocyte colony-stimulating factor (G-CSF) reduces not only gram-negative but also gram-positive infection-associated pro-inflammatory cytokine release by interaction between Kupffer cells and leukocytes

Inflammation Research

Volumn 53, Issue 5, 2004, Pages 205-210

  Busch, C J ^a   Wanner, G A ^b   Menger, M D ^c   Vollmar, B ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Bioassay; Cyclophosphamide; Interleukin 1; Interleukin 6; Leukocytes; Neutropenia; Sepsis; TNF

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL COMMUNICATION; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; KUPFFER CELL; LEUKOCYTE; MACROPHAGE; MALE; NONHUMAN; RAT; STAPHYLOCOCCUS AUREUS; TARGET CELL;

ANIMALS; CELLS, CULTURED; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRANULOCYTE COLONY-STIMULATING FACTOR; INTERLEUKIN-1; INTERLEUKIN-6; KUPFFER CELLS; LEUKOCYTES; LIPOPOLYSACCHARIDES; MALE; NEUTROPENIA; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2442589608     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-004-1250-8     Document Type: Article

References (35)

1. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. Crit Care Med 1998; 26: 2078-86.
2. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997; 112: 321S-9S.
3. Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis. A randomized controlled trial. JAMA 2000; 283: 1723-30.
4. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor: Blood 1991; 78: 2791-808.
5. Dale DC, Liles WC, Summer WR, Nelson S. Review: Granulocyte colony-stimulating factor - role and relationships in infectious diseases. J Infect Dis 1995; 172: 1061-75.
6. Lundblad R, Nesland JM, Giercksky KE. Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Crit Care Med 1996; 24: 820-6.
7. Fink MP, O'Sullivan BP, Menconi MJ, Wollert SP, Wang H, Youssef ME, et al. Effect of granulocyte colony-stimulating factor on systemic and pulmonary responses to endotoxin in pigs. J Trauma 1993; 34: 571-7.
8. Eichacker PQ, Waisman Y, Natanson C, Farese A, Hoffman WD, Banks SM, et al. Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis. J Appl Physiol 1994; 77: 2366-73.
9. Haberstroh J, Breuer H, Lücke I, Massarrat K, Früh R, Mand U, et al. Effect of recombinant human granulocyte colony-stimulating factor on hemodynamic and cytokine response in a porcine model of Pseudomonas sepsis. Shock 1995; 4: 216-24.
10. Barsig J, Bundschuh DS, Hartung T, Bauhofer A, Sauer A, Wendel A. Control of fecal peritoneal infection in mice by colony-stimulating factors. J Infect Dis 1996; 74: 790-9.
11. Vollmar B, Messner S, Wanner GA, Hartung T, Menger MD. Immunomodulatory action of G-CSF in a rat model of endotoxin-induced liver injury: an intravital microscopic analysis of Kupffer cell and leukocyte response. J Leukoc Biol 1997; 62: 710-8.
12. Vollmar B, Pradarutti S, Nickels RM, Menger MD. Age-associated loss of immunomodulatory protection by granulocyte-colony stimulating factor in endotoxic rats. Shock 2002; 18: 348-54.
13. Gross-Weege W, Weiss M, Schneider M, Wenning M, Harms B, Dumon K, et al. Safety of a low-dosage Filgrastim (rhG-CSF) treatment in non-neutropenic surgical intensive care patients with an inflammatory process. Intensive Care Med 1997; 23: 16-22.
14. Hartung T, Von Aulock S, Schneider C, Faist E. How to leverage an endogenous immune defense mechanism: the example of granulocyte colony-stimulating factor. Crit Care Med. 2003; 31: S65-75.
15. Gorgen I, Hartung T, Leist M, Niehorster M, Tiegs G, Uhlig S, et al. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. J Immunol 1992; 49: 918-24.
16. Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T. Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood 2000; 95: 270-6.
17. Kawada N, Mizoguchi Y, Kobayashi K, Morisawa S, Monna T, Yamamoto S. Interferon gamma modulates production of interleukin 1 and tumor necrosis factor by murine Kupffer cells. Liver 1991; 11: 42-7.
18. Wanner GA, Ertel W, Müller P, Höfer Y, Leiderer R, Menger MD, et al. Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock 1996; 5: 34-40.
19. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170: 1627-33.
20. Shalaby MR, Waage A, Aarden L, Espevik T. Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol 1989; 53: 488-98.
21. Hartung T, Docke WD, Gantner F, Krieger G, Sauer A, Stevens P, et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995; 85: 2482-9.
22. Boneberg EM, Hartung T. Granulocyte colony-stimulating factor attenuates LPS-stimulated IL-1beta release via suppressed processing of proIL-1beta, whereas TNF-alpha release is inhibited on the level of proTNF-alpha formation. Eur J Immunol 2002; 32: 1717-25.
23. Terashima T, Soejima K, Waki Y, Nakamura H, Fujishima S, Suzuki Y, et al. Neutrophils activated by granulocyte colony-stimulating factor suppress tumor necrosis factor-alpha release from monocytes stimulated by endotoxin. Am J Respir Cell Mol Biol 1995; 13: 69-73.
24. Kreutz M, Ackermann U, Hauschildt S, Krause SW, Riedel D, Bessler W, et al. A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and Staphyloccous aureus in human monocytes. Immunology 1997; 92: 396-401.
25. De Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci USA 1995; 92: 10359-63.
26. Wang ZM, Liu C, Dziarski R. Chemokines are the main proinflammatory mediators in human monocytes activated by Staphylococcus aureus, peptidoglycan, and endotoxin. J Biol Chem 2000; 275: 20260-7.
27. Wang JE, Jorgensen PF, Almlof M, Thiemermann C, Foster SJ, Aasen AO, Solberg R. Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect Immun 2000; 68: 3965-70.
28. Karzai W, von Specht BU, Parent C, Haberstroh J, Wollersen K, Natanson C, et al. G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 1999; 159: 1377-82.
29. Mooney DP, Gamelli RL, O'Reilly M, Hebert JC. Recombinant human granulocyte colony-stimulating factor and pseudomonas burn wound sepsis. Arch Surg 1988; 123: 1353-7.
30. Villa P, Shaklee CL, Meazza C, Agnello D, Ghezzi P, Senaldi G. Granulocyte colony-stimulating factor and antibiotics in the prophylaxis of a murine model of polymicrobial peritonitis and sepsis. J Infect Dis 1998; 178: 471-7.
31. Haberstroh J, Wiese K, Geist A, Dursunoglu GB, Gippner-Steppert C, Jochum M, et al. Effect of delayed treatment with recombinant human granulocyte colony-stimulating factor on survival and plasma cytokine levels in a non-neutropenic porcine model of Pseudomonas aeruginosa sepsis. Shock 1998; 9: 128-34.
32. Jochum M, Gippner-Steppert C, Machleidt W, Fritz H. The role of phagocyte proteinases and proteinase inhibitors in multiple organ failure. Am J Respir Crit Care Med 1994; 150: 123-30.
33. Root RK, Dale DC. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 1999; 179: S342-52.
34. Arslan E, Yavuz M, Dalay C. The relationship between tumor necrosis factor (TNF)-alpha and survival following granulocyte-colony stimulating factor (G-CSF) administration in burn sepsis. Burns 2000; 26: 521-41.
35. Bernstein HM, Calhoun DA, Christensen RD. Use of myeloid colony-stimulating factors in neonates with septicemia. Curr Opin Pediatr 2002; 14: 91-4.